Subsequently, other TGF-β signaling components, e.g., TGF-β receptors [51] and SMADs (SMAD2 and SMAD3), were found to be mutated in various cancers, including bladder, colon, breast, esophageal, stomach, brain, liver, and lung cancers [52]. The gene discussed is SMAD2; the disease is lung cancer.